Frequency of Metabolic Associated Fatty Liver Disease among Chronic Kidney Disease Patients in Upper Egypt

• Published in: SVU - International Journal of Medical Sciences (Online) Vol. 5; no. 2; pp. 189 - 199
• Main Authors: Bazeed, Shamardan Ezzeldin S., Fayed, Hanan Mahmoud, Hashim, AbdelKader Ahmed, Abdelhady, Omima Rabea Abdelrady, Arafat, Shimaa
• Format: Journal Article
• Language: English
• Published: South Valley University, Faculty of Medicine 01.07.2022
• Subjects: metabolic associated fatty liver disease; chronic kidney disease; estimated glomerular filtration
• ISSN: 2636-3402; 2735-427X; 2636-3402
• DOI: 10.21608/svuijm.2022.128484.1299

Background: Chronic kidney disease (CKD) and metabolic-associated fatty liver disease (MAFLD) are increasing chronic illnesses that contribute to a variety of major cardio-metabolic risk factors and pathogenic processes. Objectives: To estimate the frequency of MAFLD and its risk factors among CKD Patients in Upper Egypt. Patients and methods: a case-control study entangled 200 individuals with CKD and 60 person without as a control. All participants underwent a thorough history, physical examination, and laboratory testing which incorporate complete blood count, assessment of neutrophil-lymphocyte ratio (NLR), liver enzymes (ALT, AST), kidney function, estimated glomerular filtration rate (eGFR), and lipid profile. Pelvic-abdominal ultrasound and fibroscan were executed. Results: We found a significantly increased proportion of MAFLD, HbA1c and NLR values in the cases group when compared with the control group, where a high prevalence of steatosis and liver stiffness among CKD patients. Multivariate logistic regression analysis demonstrated that high BMI, elevated LDL, elevated liver enzymes (AST & ALT) were predictive risk factors for the existence of MAFLD in the CKD patients. Conclusion: There is a statistically significant correlation between CKD and MAFLD in the form of increased prevalence of MAFLD in CKD patients.